Clinical trials: Dementia Prevention, open to volunteers
Alzheimer Disease, Family Members
Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG.
- Trial name
- NCT05776641
- Testing
- GENUS
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Diabetes, Alzheimer Disease
The Diabetes Prevention Program Outcomes Study AD/ADRD Project
The DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for…
- Conditions
- Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia
- Trial name
- DPPOS-4 (NCT05704309)
- Where
- 27 sites in United States
- Volunteers
- 1,976 people, healthy volunteers welcome
- Sponsor
- Marinella Temprosa
Older Adults at High Risk for MCI, Older Adults With Mild to Moderate Level of Dementia
STRONGER 60+: Assessing the Clinical Effectiveness and Delivery of an Adapted FINGER Model for Brain Health in Primary Care
Background: The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was the first to show that multidomain lifestyle interventions can enhance brain health and reduce cognitive decline.
- Trial name
- STRONGER (NCT07117916)
- Testing
- Supervised nutritional guidance, physical exercise, cognitive training, social engagement, and management of vascular and metabolic risk factors., Self-Guided
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Dementia Risk Factors, Prevention
The REMINDER4Care Program for Older Adults Supported by Residential and Daycare Facilities
Dementia incidence is rising, posing a public health challenge, but 45% of cases can be prevented by addressing modifiable risk factors.
- Conditions
- Dementia Risk Factors, Prevention, Cognitive Health
- Trial name
- REMINDER4Care (NCT06922071)
- Testing
- REMINDER4Care
- Where
- Portugal
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Coimbra
Alzheimer's Disease
Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants
Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression.
- Trial name
- NCT02685969
- Testing
- 18F-Flutemetamol & 18F-FDG
- Where
- Spain
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Alzheimers Disease, Dementia
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU-002 (NCT06647498)
- Testing
- Remternetug
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Parkinson Disease, Prodromal Stage
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases.
- Conditions
- Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases
- Trial name
- ALPHA-FIT (NCT07324330)
- Testing
- Increase of physical activity volume and intensity with the use of a motivational smartphone application
- Where
- Germany
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Cognitive Dysfunction, Alzheimer Disease
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults…
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of
- Trial name
- NCT07392723
- Testing
- Alpha-Linolenic Acid (2.6 g/day)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Michal Schnaider Beeri, Ph.D.
Dementia Prevention, Subjective Cognitive Impairment
The Brain Health PRO Online Risk Factor Reduction Study to Prevent Dementia
This study will recruit participants at risk for dementia to participate in an online educational program called Brain Health PRO (BHPro).
- Conditions
- Dementia Prevention, Subjective Cognitive Impairment, Mild Cognitive Impairment, Cognitive Change
- Trial name
- BHPROOF (NCT07364019)
- Testing
- Brain Health PRO
- Where
- Canada
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Alzheimer's Disease, Dementia
Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies
The Alzheimer's Prevention Registry (www.endALZnow.org) will collect contact and demographic information on individuals. The objective is to provide information the latest news and advances in Alzheimer's prevention research, and…
- Trial name
- APR (NCT02022943)
- Where
- United States
- Volunteers
- 500,000 people, healthy volunteers welcome
- Sponsor
- Banner Health
Dementia, Alzheimer Type
Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"
The RAATE proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group.
- Trial name
- RAATE (NCT03890861)
- Testing
- Physical activity, Successful Aging
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Pennington Biomedical Research Center
Alzheimer Disease
Epidemiology and Biomarker Study in Alzheimer's Disease
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
- Trial name
- ANCHOR-AD (NCT07142954)
- Testing
- P-tau217 Test
- Where
- 4 sites in United States, Japan
- Volunteers
- 3,400 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease (AD)
Daridorexant for Alzheimer Disease Prevention
This study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease.
- Trial name
- PAD-DORA (NCT07213349)
- Testing
- Daridorexant 50 mg
- Where
- Canada
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
MCI, SCD
Identification of Neuroinflammation and Neuroimaging Biomarkers Through Data Driven Artificial Intelligence Techniques for Unraveling the Heterogeneity of Aged Subjects at Risk of Dementia and to Better Inform Prevention Strategies
SCD and MCI are very heterogeneous conditions, which can be prodromal to different types of dementia. The application of data driven clustering methods on neuroimaging and inflammatory data aims at identifying the features…
- Conditions
- MCI, SCD, Healthy
- Trial name
- NCT06746909
- Testing
- Multidomain cognitive training and physical training
- Where
- Italy
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- IRCCS Fondazione Stella Maris
Prevention, Dementia
Kimel Family Centre for Brain Health and Wellness
Participants (n=450; aged 50+; without a diagnosis of dementia; sufficiently fluent in English to complete the assessments and engage in programming) receive a comprehensive dementia risk assessment, including nonmodifiable and…
- Trial name
- NCT06933667
- Testing
- Physical Activity, Brain-healthy Eating, Cognitive Engagement
- Where
- Canada
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Baycrest
Alzheimers Disease, Dementia
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation.
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT05552157)
- Testing
- Remternetug (SC)
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Violence, Adolescent
Addressing Root Causes for Gun Violence Prevention (ARC-GVP)
The goal of this study is to help build the evidence base for a locally-relevant youth firearm violence prevention program in Washington D.C., a city experiencing disparities in youth firearm violence outcomes.
- Conditions
- Violence, Adolescent, Firearm Injury, Aggression
- Trial name
- NCT05887973
- Testing
- The T.R.I.G.G.E.R Project
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Preclinical Alzheimer's Disease, Alzheimer's Disease (AD)
Alzheimer's Plasma Extension
The goal of this observational study is to learn how Alzheimer's disease-related blood biomarkers, brain amyloid, and memory and thinking abilities change over time.
- Trial name
- APEX (NCT06416072)
- Testing
- NAV4694
- Where
- 56 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease, Mild Cognitive Impairment
RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β
The goal of this clinical trial is to evaluate whether oral resveratrol, quercetin, and curcumin (RQC) can prevent the accumulation of retinal amyloid-β and/or cognitive decline over 24 months in adults aged 50-90 with Stage 1 or…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- NCT06470061
- Testing
- Resveratrol, Quercetin, and Curcumin (RQC), Curcumin
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zaparackas and Knepper LTD
Dementia, Mild, Accidental Falls
Development of Pressure Sensor Based Dementia and Fall Prevention Program for Older Adults
The goal of this intervention program is to test the effectiveness of pressure sensor based dementia and fall prevention program for improving cognitive and physical functions of community dwelling older adults.
- Conditions
- Dementia, Mild, Accidental Falls, Mild Cognitive Impairment
- Trial name
- NCT06664229
- Testing
- Fall and dementia prevention exercise
- Where
- South Korea
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Sunmi Song